Journal
THROMBOSIS RESEARCH
Volume 148, Issue -, Pages 118-124Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2016.11.004
Keywords
Retinal vein occlusion; Pathophysiology; Treatment; Anticoagulation
Categories
Funding
- Pfizer
- Leo Pharma
- Bayer
- Daiichi-Sankyo
- Novartis
- Celgene
- Alexion Pharmaceuticals
Ask authors/readers for more resources
Retinal vein occlusion is a common and important cause of vision loss. In general, knowledge about this condition is scant within an internist's practice but the condition is relevant because of its association with other chronic ailments. A diagnosis of RVO should prompt the investigation of conditions needing chronic management in these patients. In this review we summarize the clinical presentation of RVO, its classification, associated risk factors, and treatment focused in the internist's scope of practice. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available